Organon Is Ready To Launch And Makes The Case To Investors
Established Products Will Account For The Majority Of Revenues
Merck & Co. plans to spin off Organon in June as a diversified health care company focused on women's health, biosimilars and established products.
You may also be interested in...
Increases in employee numbers often go hand-in-hand with valuation rises as companies are acquired or product success demand increases in sales staff or manufacturing capacity. However, this is not always the case.
A year after Organon spun out of Merck, the company has delivered on its financial guidance, generated double-digit biosimilars sales growth and executed six deals to grow in women’s health.
News and views from day one of the BIO annual meeting include reflections on how the biopharma industry is adjusting to current conditions. EY's annual Beyond Borders reports predicts continued success based on past performance, CBRE tracks how the life science industry is spreading out, and Organon's CEO discusses the company's biosimilars deal with Henlius.